HRP20030910B1 - Tartarate salts 5,8,14-triazatetracyclo {10.3.1.02,11.04,9}-hexadeca-2(11), 3,5,7,9-pentaene and pharmaceutical compositions thereof - Google Patents
Tartarate salts 5,8,14-triazatetracyclo {10.3.1.02,11.04,9}-hexadeca-2(11), 3,5,7,9-pentaene and pharmaceutical compositions thereofInfo
- Publication number
- HRP20030910B1 HRP20030910B1 HR20030910A HRP20030910A HRP20030910B1 HR P20030910 B1 HRP20030910 B1 HR P20030910B1 HR 20030910 A HR20030910 A HR 20030910A HR P20030910 A HRP20030910 A HR P20030910A HR P20030910 B1 HRP20030910 B1 HR P20030910B1
- Authority
- HR
- Croatia
- Prior art keywords
- triazatetracyclo
- pentaene
- hexadeca
- pharmaceutical compositions
- tartarate salts
- Prior art date
Links
- JQSHBVHOMNKWFT-UHFFFAOYSA-N varenicline Chemical compound C12=CC3=NC=CN=C3C=C2C2CC1CNC2 JQSHBVHOMNKWFT-UHFFFAOYSA-N 0.000 title abstract 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical class OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 150000003892 tartrate salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Diabetes (AREA)
- Virology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Nutrition Science (AREA)
- Psychology (AREA)
- AIDS & HIV (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Child & Adolescent Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Communicable Diseases (AREA)
- Gastroenterology & Hepatology (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US29086101P | 2001-05-14 | 2001-05-14 | |
PCT/IB2002/001437 WO2002092089A1 (en) | 2001-05-14 | 2002-04-26 | Tartrate salts of 5,8,14-triazatetracyclo {10.3.1.0?2,11.04,9¿}-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
HRP20030910A2 HRP20030910A2 (en) | 2004-02-29 |
HRP20030910B1 true HRP20030910B1 (en) | 2011-11-30 |
Family
ID=23117845
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HR20030910A HRP20030910B1 (en) | 2001-05-14 | 2003-11-10 | Tartarate salts 5,8,14-triazatetracyclo {10.3.1.02,11.04,9}-hexadeca-2(11), 3,5,7,9-pentaene and pharmaceutical compositions thereof |
Country Status (48)
Families Citing this family (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR9814592B1 (pt) * | 1997-12-31 | 2010-06-01 | composto azapolicìclico condensado com arila, composição farmacêutica contendo o mesmo e seu uso na fabricação de um medicamento. | |
CN1596128A (zh) * | 2001-11-30 | 2005-03-16 | 辉瑞产品公司 | 5,7,14-三氮杂四环[10.3.1.0(2,11).0(4,9)]-十六碳-2(11)3,5,7,9-五烯的药物组合物 |
BRPI0410219A (pt) * | 2003-05-20 | 2006-05-09 | Pfizer Prod Inc | composições farmacêuticas de vareniclina |
WO2005061519A1 (en) * | 2003-12-19 | 2005-07-07 | Takeda San Diego, Inc. | Kinase inhibitors |
JP2007533753A (ja) * | 2004-04-23 | 2007-11-22 | タケダ サン ディエゴ インコーポレイテッド | インドール誘導体及びキナーゼ阻害剤としてのその使用 |
MXPA06015112A (es) * | 2004-06-30 | 2007-02-08 | Lilly Co Eli | D-tartrato de 1-(indol-6-carbonil-d-fenilglicinil)-4-(1-metilpiperidin-4-il) piperazina. |
EP1778669A2 (de) * | 2004-08-18 | 2007-05-02 | Takeda San Diego, Inc. | Kinase-inhibitoren |
BRPI0515932A (pt) * | 2004-10-15 | 2008-08-12 | Pfizer Prod Inc | composições e métodos para distribuição intranasal, bucal, sublingual e pulmonar de vareniclina |
US7713973B2 (en) * | 2004-10-15 | 2010-05-11 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
JP2008531540A (ja) * | 2005-02-24 | 2008-08-14 | ファイザー・プロダクツ・インク | 高純度置換キノキサリンの調製 |
US20110086086A1 (en) * | 2005-07-26 | 2011-04-14 | Pfizer Inc | Transdermal system for varenicline |
US8119655B2 (en) * | 2005-10-07 | 2012-02-21 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
WO2007098273A2 (en) * | 2006-02-21 | 2007-08-30 | Teva Pharmaceutical Industries Ltd. | Novel crystalline forms of armodafinil and preparation thereof |
EP2223925A1 (de) * | 2006-10-09 | 2010-09-01 | Takeda Pharmaceutical Company Limited | Kinase-Inhibitoren |
SG158147A1 (en) | 2006-10-09 | 2010-01-29 | Takeda Pharmaceutical | Kinase inhibitors |
JP2010527907A (ja) * | 2006-11-09 | 2010-08-19 | ファイザー・プロダクツ・インク | ニコチン様中間体の多形体 |
US20090062257A1 (en) * | 2007-08-29 | 2009-03-05 | Protia, Llc | Deuterium-enriched varenicline |
WO2009045488A2 (en) * | 2007-10-02 | 2009-04-09 | Teva Pharmaceutical Industries Ltd. | Novel crystalline forms of armodafinil and preparation thereof |
US20090215787A1 (en) * | 2008-02-22 | 2009-08-27 | Mai De Ltd. | Preparations of new polymorphic forms of varenicline tartrate |
WO2009109651A1 (en) * | 2008-03-06 | 2009-09-11 | Medichem, S.A. | SALTS OF A PYRAZINO[2,3-h][3]BENZAZEPINE DERIVATIVE |
WO2009111623A2 (en) * | 2008-03-06 | 2009-09-11 | Dr. Reddy's Laboratories Ltd. | Amorphous varenicline tartrate |
US9463190B2 (en) * | 2008-03-31 | 2016-10-11 | University Of South Florida | Methods of treating disease-induced ataxia and non-ataxic imbalance |
US8039620B2 (en) | 2008-05-22 | 2011-10-18 | Teva Pharmaceutical Industries Ltd. | Varenicline tosylate, an intermediate in the preparation process of varenicline L-tartrate |
US20090318460A1 (en) * | 2008-05-26 | 2009-12-24 | Glenmark | Amorphous varenicline tartrate and process for the preparation thereof |
US20090318695A1 (en) * | 2008-06-19 | 2009-12-24 | Vinod Kumar Kansal | Processes for the preparation of varenicline and intermediates thereof |
US20100010221A1 (en) * | 2008-07-10 | 2010-01-14 | Revital Lifshitz-Liron | Processes for purifying varenicline l-tartrate salt and preparing crystalline forms of varenicline l-tartrate salt |
EP2334679A1 (de) * | 2008-09-01 | 2011-06-22 | Actavis Group PTC EHF | Verfahren zur herstellung von vareniclin, vareniclinzwischenprodukte und pharmazeutisch unbedenkliche salze davon |
US20120093887A1 (en) | 2009-06-10 | 2012-04-19 | Actavis Group Ptc Ehf | Amorphous varenicline tartrate co-precipitates |
RU2012102052A (ru) | 2009-06-22 | 2013-11-20 | Тева Фармасьютикал Индастриз Лтд. | Твердые формы солей варениклина и способы их получения |
EP2545054A1 (de) | 2010-03-09 | 2013-01-16 | Actavis Group Ptc Ehf | Hochreines vareniclin oder weitgehend von methylvareniclinunreihheiten freies pharmazeutisch akzeptables salz daraus |
WO2011140431A1 (en) | 2010-05-06 | 2011-11-10 | Teva Pharmaceutical Industries Ltd. | Varenicline salts and crystal forms thereof |
CN104334561B (zh) | 2012-04-13 | 2016-06-22 | 连云港金康和信药业有限公司 | 化合物jk12a及其制备 |
KR101663550B1 (ko) * | 2014-06-11 | 2016-10-07 | 조선대학교산학협력단 | 주석산을 유효성분으로 포함하는 고혈압 예방 또는 치료용 약학조성물 및 건강기능식품 |
KR101724301B1 (ko) | 2016-11-22 | 2017-04-10 | 주식회사 한서켐 | 바레니클린 살리실산염의 i형 결정 및 그 제조방법 |
WO2018154395A2 (en) | 2018-06-11 | 2018-08-30 | Alvogen Malta Operations (Row) Ltd | Controlled release pharmaceutical composition of varenicline |
EP4142734A1 (de) | 2020-04-28 | 2023-03-08 | Oyster Point Pharma, Inc. | Lokale verabreichung von nikotinischen acetylcholinrezeptoragonisten zur hemmung von coronavirusinfektionen |
KR20240038022A (ko) | 2021-08-20 | 2024-03-22 | 비위트 파마슈티컬 컴퍼니 리미티드 | 니트로사민 불순물, 니트로사민 불순물 생성을 줄일 수 있는 바레니클린 약학 조성물 및 그 제조와 응용 |
KR20230068877A (ko) | 2021-11-11 | 2023-05-18 | 주식회사 아울바이오 | 고용량 바레니클린을 포함하는 미립구 및 이의 제조방법 및 이를 포함하는 약학적 조성물 |
CN113980020B (zh) * | 2021-11-22 | 2023-05-09 | 浙江车头制药股份有限公司 | 一种酒石酸伐尼克兰晶型的制备方法 |
WO2023275413A2 (en) | 2021-12-23 | 2023-01-05 | Medichem, S.A. | Solid pharmaceutical formulations of varenicline |
US11602537B2 (en) | 2022-03-11 | 2023-03-14 | Par Pharmaceutical, Inc. | Varenicline compound and process of manufacture thereof |
EP4241775A1 (de) | 2022-03-11 | 2023-09-13 | Par Pharmaceutical, Inc. | Tablette mit vareniclin und verfahren zur herstellung davon |
WO2024095172A1 (en) | 2022-11-04 | 2024-05-10 | Pfizer Inc. | Prodrugs of varenicline and compounds containing vulnerable amines |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999035131A1 (en) * | 1997-12-31 | 1999-07-15 | Pfizer Products Inc. | Aryl fused azapolycyclic compounds |
EP1078637A2 (de) * | 1999-08-27 | 2001-02-28 | Pfizer Products Inc. | Zusammensetzungen zur Behandlung und Vorbeugung von Nikotinabhängigkeit enthaltend einen Nicotin-Rezeptor-Agonisten und ein Azneimittel mit antidepressiver oder Angstlösender Wirkung |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3471503A (en) | 1967-05-05 | 1969-10-07 | Mcneilab Inc | 1,2,3,5,6,7-hexahydro-4-phenethyl-2,6-methano-4h-4- benzazonin-12-ols |
CZ20011726A3 (cs) * | 2000-05-26 | 2002-02-13 | Pfizer Products Inc. | Způsob reakční krystalizace, který umoľňuje řídit velikost částic |
-
2002
- 2002-04-26 HU HU0304088A patent/HU229867B1/hu unknown
- 2002-04-26 GE GE5341A patent/GEP20053712B/en unknown
- 2002-04-26 AT AT02722625T patent/ATE302607T1/de active
- 2002-04-26 PL PL366551A patent/PL214876B1/pl unknown
- 2002-04-26 UA UA20031110266A patent/UA73422C2/uk unknown
- 2002-04-26 ES ES02722625T patent/ES2246396T3/es not_active Expired - Lifetime
- 2002-04-26 BR BR0209605-6A patent/BR0209605A/pt not_active IP Right Cessation
- 2002-04-26 KR KR1020037014754A patent/KR100551184B1/ko active IP Right Review Request
- 2002-04-26 OA OA1200300289A patent/OA12599A/en unknown
- 2002-04-26 PT PT02722625T patent/PT1392307E/pt unknown
- 2002-04-26 DE DE60205742T patent/DE60205742T2/de not_active Expired - Lifetime
- 2002-04-26 WO PCT/IB2002/001437 patent/WO2002092089A1/en active IP Right Grant
- 2002-04-26 EP EP02722625A patent/EP1392307B1/de not_active Expired - Lifetime
- 2002-04-26 CA CA002447405A patent/CA2447405C/en not_active Expired - Lifetime
- 2002-04-26 EA EA200301121A patent/EA005528B1/ru active Protection Beyond IP Right Term
- 2002-04-26 ME MEP-2008-717A patent/ME00466B/me unknown
- 2002-04-26 SK SK1336-2003A patent/SK287170B6/sk not_active IP Right Cessation
- 2002-04-26 IL IL15793302A patent/IL157933A0/xx unknown
- 2002-04-26 EE EEP200300556A patent/EE05441B1/xx unknown
- 2002-04-26 CN CNB028099125A patent/CN100370987C/zh not_active Expired - Lifetime
- 2002-04-26 SI SI200230189T patent/SI1392307T1/sl unknown
- 2002-04-26 RS YUP-867/03A patent/RS50814B/sr unknown
- 2002-04-26 CZ CZ2003-2916A patent/CZ304763B6/cs not_active IP Right Cessation
- 2002-04-26 JP JP2002589006A patent/JP3779682B2/ja not_active Expired - Lifetime
- 2002-04-26 AU AU2002253482A patent/AU2002253482B2/en not_active Expired
- 2002-04-26 DK DK02722625T patent/DK1392307T3/da active
- 2002-04-26 MX MXPA03010364A patent/MXPA03010364A/es active IP Right Grant
- 2002-04-26 NZ NZ528210A patent/NZ528210A/en not_active IP Right Cessation
- 2002-05-06 DO DO2002000392A patent/DOP2002000392A/es unknown
- 2002-05-06 US US10/139,730 patent/US6890927B2/en not_active Expired - Lifetime
- 2002-05-09 AP APAP/P/2002/002523A patent/AP1473A/en active
- 2002-05-10 PE PE2002000391A patent/PE20021065A1/es active IP Right Grant
- 2002-05-10 MY MYPI20021696A patent/MY127807A/en unknown
- 2002-05-10 GT GT200200084A patent/GT200200084A/es unknown
- 2002-05-13 AR ARP020101734A patent/AR033635A1/es active IP Right Grant
- 2002-05-13 TW TW091109919A patent/TWI262078B/zh not_active IP Right Cessation
- 2002-05-13 EG EG20020483A patent/EG24228A/xx active
- 2002-05-14 PA PA20028545101A patent/PA8545101A1/es unknown
-
2003
- 2003-07-08 TN TNPCT/IB2002/001437A patent/TNSN03113A1/fr unknown
- 2003-09-15 IL IL157933A patent/IL157933A/en active IP Right Grant
- 2003-09-15 IS IS6957A patent/IS2217B/is unknown
- 2003-09-16 ZA ZA200307235A patent/ZA200307235B/en unknown
- 2003-09-22 CR CR7080A patent/CR7080A/es not_active Application Discontinuation
- 2003-11-10 HR HR20030910A patent/HRP20030910B1/xx not_active IP Right Cessation
- 2003-11-10 MA MA27389A patent/MA27020A1/fr unknown
- 2003-11-11 BG BG108343A patent/BG66408B1/bg unknown
- 2003-11-13 NO NO20035036A patent/NO326148B1/no not_active IP Right Cessation
- 2003-11-14 EC EC2003004850A patent/ECSP034850A/es unknown
- 2003-11-14 EC EC2003004849A patent/ECSP034849A/es unknown
-
2004
- 2004-07-28 HK HK04105577A patent/HK1062645A1/xx not_active IP Right Cessation
-
2005
- 2005-02-28 US US11/069,724 patent/US7265119B2/en not_active Expired - Lifetime
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999035131A1 (en) * | 1997-12-31 | 1999-07-15 | Pfizer Products Inc. | Aryl fused azapolycyclic compounds |
EP1078637A2 (de) * | 1999-08-27 | 2001-02-28 | Pfizer Products Inc. | Zusammensetzungen zur Behandlung und Vorbeugung von Nikotinabhängigkeit enthaltend einen Nicotin-Rezeptor-Agonisten und ein Azneimittel mit antidepressiver oder Angstlösender Wirkung |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20030910B1 (en) | Tartarate salts 5,8,14-triazatetracyclo {10.3.1.02,11.04,9}-hexadeca-2(11), 3,5,7,9-pentaene and pharmaceutical compositions thereof | |
RS51444B (sr) | JEDINJENJA KOJA SADRŽE LAKTAM I NJIHOVI DERIVATI KAO INHIBITORI FAKTORA Xa | |
PL370913A1 (en) | Pharmaceutical compositions of 5,7,14-triazatetracyclo[10.3.1.0(2,11).0(4,9)]-hexadeca-2(11)3,5,7,9-pentaene | |
ATE301653T1 (de) | Pyrazolopyridine | |
EE200300403A (et) | N-asendatud mittearomaatne heterotsükliline ühend, seda sisaldav ravimkompositsioon ning ühendi kasutamine ravimina | |
ATE264852T1 (de) | Chinolinderivate als antibakterielle mittel | |
PL374325A1 (en) | Succinic acid salts of 5,8,14-triazatetracyclo[10.3.1.0 2,11 .0 4,9 ]-hexadeca-2(11),3,5,7,9,-pentaene and pharmaceutical compositions thereof | |
HRP20020198B1 (en) | Moxifloxacin formulation containing common salt | |
EE200300557A (et) | 5,8,14-triasatetratsüklo [10,3,1,0 2,11 ,0 4,9]heksadeka-2(11),3,5,7,9-pentaeeni tsitraatsool | |
AR027296A1 (es) | Derivados de 4-heteroaril-1,4-diazabiciclo[3.2.2]nonano, su preparacion y su aplicacion terapeutica | |
HRPK20040372B3 (en) | Crystalline sodium salt of telmisartan and the use of the same as an angiotensin antagonist | |
SE0102440D0 (sv) | New compound | |
NO20001781L (no) | 3-amino-3-arylpropan-1-og lignende-derivater, deres fremstilling og anvendelse | |
CA2412596A1 (en) | Cyclic gmp-specific phosphodiesterase inhibitors | |
HRPK20040528B3 (en) | Use of norepinephrine reuptake inhibitors for the treatment of cognitive failure | |
ATE274515T1 (de) | Pyrazolopyridinderivate | |
SE0102057D0 (sv) | New Salts I | |
NO20052562L (no) | Anvendelse av distrontiumsalter av 2-[N,N-di(karboksylmetyl)amino]-3-cyano-4-karboksylmetyl-tiofen-5-karboksylsyre for fremstilling av medikamenter for behandlingen av gastro-duodenal smerte. | |
HRP20080179T3 (en) | Novel imidazopyridine compound ii with therapeutic effect | |
NO20041878L (no) | Karboksylsyrederivat-forbindelser og legemidler inneholdende de samme som den aktive bestanddel. | |
SE0100295D0 (sv) | New compounds |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A1OB | Publication of a patent application | ||
ARAI | Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application | ||
B1PR | Patent granted | ||
ODRP | Renewal fee for the maintenance of a patent |
Payment date: 20190402 Year of fee payment: 18 |
|
ODRP | Renewal fee for the maintenance of a patent |
Payment date: 20200326 Year of fee payment: 19 |
|
ODRP | Renewal fee for the maintenance of a patent |
Payment date: 20210414 Year of fee payment: 20 |
|
PB20 | Patent expired after termination of 20 years |
Effective date: 20220426 |